Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1094

Shown on this page

Current sort

Stored official records

Conditions: Chronic Renal Disease, End Stage Renal Disease (ESRD), Hemodialysis, Kidney Failure
Interventions: InnAVasc Arteriovenous Graft (IG) surgical implant; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 22
States / cities: Phoenix, Arizona • La Mesa, California • Sarasota, Florida + 17 more

Conditions: Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • South Pasadena, California + 18 more

Conditions: Knee Arthroplasty
Interventions: Knee Flexion, Standard Care; Other · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 22 more

Conditions: Advanced Solid Tumor
Interventions: M0324, Pembrolizumab, mFOLFIRINOX; Biological · Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • San Antonio, Texas

Conditions: Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Interventions: Screening; Other
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 21 more

Conditions: Anxiety, Cardiac Arrest (CA), Caregivers, Depression, Emotional Distress, Mindfulness, Resilience, Survivorship
Interventions: Recovering Together after Cardiac Arrest 1, Recovering Together after Cardiac Arrest 2; Behavioral · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: High-risk Prostate Cancer, Prostate Cancer
Interventions: Darolutamide, Lupron, Pembrolizumab; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity or Overweight, Ulcerative Colitis
Interventions: Mirikizumab, Placebo, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 9 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Teclistamab; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Crohn's Disease, Inflammatory Bowel Diseases, Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Stored official records

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Knee Positioning After Total Knee Replacement

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Mind-body Resilience Program for Cardiac Arrest Survivors and Their Caregivers: Recovering Together After Cardiac Arrest

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

About this Mount Sinai institution page